Therapy Areas: Diabetes
Oramed Pharmaceuticals reveals results from proof-of-concept study for oral leptin
24 December 2020 -

It was reported on Wednesday that Oramed Pharmaceuticals Inc (Nasdaq: ORMP) (TASE: ORMP), a Jerusalem-based clinical-stage pharmaceutical company, has revealed results from a proof-of-concept study for its oral leptin drug candidate.

The product was approved by Israel's Ministry of Health. The single dose study assessed oral leptin's safety and pharmacodynamics (glucagon and glucose reduction) in type 1 diabetic patients.

The study enrolled ten patients, with seven randomised to receive one capsule of leptin and three randomised to receive a placebo. The study revealed that patients who received leptin on average had a reduction in glucose as compared to the placebo group during the first 30-180 minutes following dosing.

Login
Username:

Password:


Related Headlines

Colombia approves Pfizer-BioNTech COVID-19 vaccine for emergency use

VisionQuest Biomedical Inc wins FDA 510(k) clearance to market the Image Quality Analyzer software

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80m Patient Encounters in the US Annually

Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS

The FDA approves first generic glucagon to treat severe hypoglycemia to improve competition and access to more affordable medicines

Health Canada Accepts Vertex New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis

EOM Pharmaceuticals Files Pre-IND Meeting Request with US FDA to Evaluate Plans for a Phase 2 Clinical Trial of Its Investigational Dual-Acting, Broad-Spectrum Immunomodulator in COVID-19 Patients

Oramed Pharmaceuticals reveals results from proof-of-concept study for oral leptin

US FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

Peru to resume COVID-19 vaccine trials of China's Sinopharm after lifting of suspension

Glytec Publishes COVID-19 Research to Study the 'Opportunity Window' for Treating Hospitalized Patients with Diabetes or Hyperglycemia

Medtronic names new executive vice president and president, Cardiovascular Portfolio

Peru suspends trail of Sinopharm's COVID-19 vaccine trial after patient reports decrease in muscle strength in his legs

Tobin Scientific, PHCbi Collaborate on Solution for Regional Distribution of COVID-19 Vaccine to Address Ultra Low Temperature Requirements

Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy